ID29046A - Asam 2,3,4,5-tetrahidro-1h-(1,4)benzodiazepin-3-hidroksamat sebagai matriks penghambat metaloproteinase - Google Patents

Asam 2,3,4,5-tetrahidro-1h-(1,4)benzodiazepin-3-hidroksamat sebagai matriks penghambat metaloproteinase

Info

Publication number
ID29046A
ID29046A IDW00200101465A ID20011465A ID29046A ID 29046 A ID29046 A ID 29046A ID W00200101465 A IDW00200101465 A ID W00200101465A ID 20011465 A ID20011465 A ID 20011465A ID 29046 A ID29046 A ID 29046A
Authority
ID
Indonesia
Prior art keywords
hydroxycate
tetrahidro
metaloproteinase
hazing
benzodiazepin
Prior art date
Application number
IDW00200101465A
Other languages
English (en)
Inventor
J D Albert
E G Delossantos
J I Levin
J M Chen
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ID29046A publication Critical patent/ID29046A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
IDW00200101465A 1999-01-27 2000-01-27 Asam 2,3,4,5-tetrahidro-1h-(1,4)benzodiazepin-3-hidroksamat sebagai matriks penghambat metaloproteinase ID29046A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23908099A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
ID29046A true ID29046A (id) 2001-07-26

Family

ID=22900512

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101465A ID29046A (id) 1999-01-27 2000-01-27 Asam 2,3,4,5-tetrahidro-1h-(1,4)benzodiazepin-3-hidroksamat sebagai matriks penghambat metaloproteinase

Country Status (25)

Country Link
EP (1) EP1147095B1 (id)
JP (1) JP2002535392A (id)
KR (1) KR20010101730A (id)
CN (1) CN1197849C (id)
AR (1) AR022423A1 (id)
AT (1) ATE273288T1 (id)
AU (1) AU767039B2 (id)
BG (1) BG105736A (id)
BR (1) BR0007759A (id)
CA (1) CA2356267A1 (id)
CZ (1) CZ20012637A3 (id)
DE (1) DE60012883T2 (id)
EA (1) EA200100809A1 (id)
ES (1) ES2223470T3 (id)
HU (1) HUP0105302A3 (id)
ID (1) ID29046A (id)
IL (1) IL144168A0 (id)
NO (1) NO20013675L (id)
NZ (1) NZ511885A (id)
PL (1) PL349025A1 (id)
PT (1) PT1147095E (id)
SK (1) SK10422001A3 (id)
TR (1) TR200102131T2 (id)
WO (1) WO2000044730A1 (id)
ZA (1) ZA200104321B (id)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
BR0213736A (pt) 2001-11-01 2004-10-19 Wyeth Corp ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
MXPA05001603A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2572047C (en) 2004-07-21 2014-04-08 Applied Research Systems Ars Holding N.V. Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof
EP1781360A1 (en) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
FR2950057B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950056B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
WO2012005229A1 (ja) 2010-07-08 2012-01-12 科研製薬株式会社 N-ヒドロキシホルムアミド誘導体およびそれを含有する医薬
US9034922B2 (en) 2010-09-17 2015-05-19 The University Of Tokyo Composition for maintaining function of platelets
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂
CA3151199A1 (en) * 2019-09-19 2021-03-25 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ES2153031T4 (es) * 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US6207672B1 (en) * 1995-11-13 2001-03-27 Aventis Pharma Deutschland Gmbh Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
ES2233275T3 (es) * 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
KR100339296B1 (ko) * 1996-08-28 2002-06-03 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 억제제
ATE226573T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Heterozyklische metalloproteaseinhibitoren
DE69716934T2 (de) * 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
EP1051407A1 (en) * 1998-01-27 2000-11-15 American Cyanamid Company 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
AR022423A1 (es) 2002-09-04
PL349025A1 (en) 2002-07-01
JP2002535392A (ja) 2002-10-22
PT1147095E (pt) 2004-12-31
EP1147095B1 (en) 2004-08-11
DE60012883T2 (de) 2005-08-25
WO2000044730A1 (en) 2000-08-03
AU767039B2 (en) 2003-10-30
ATE273288T1 (de) 2004-08-15
ZA200104321B (en) 2002-08-26
TR200102131T2 (tr) 2001-12-21
CN1337952A (zh) 2002-02-27
EA200100809A1 (ru) 2002-02-28
SK10422001A3 (sk) 2002-09-10
NO20013675L (no) 2001-09-21
HUP0105302A2 (hu) 2002-07-29
DE60012883D1 (de) 2004-09-16
ES2223470T3 (es) 2005-03-01
CN1197849C (zh) 2005-04-20
BR0007759A (pt) 2001-11-13
NZ511885A (en) 2003-06-30
CA2356267A1 (en) 2000-08-03
IL144168A0 (en) 2002-05-23
KR20010101730A (ko) 2001-11-14
CZ20012637A3 (cs) 2002-04-17
NO20013675D0 (no) 2001-07-26
BG105736A (en) 2002-05-31
EP1147095A1 (en) 2001-10-24
HUP0105302A3 (en) 2002-09-30
AU3216000A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
ID29046A (id) Asam 2,3,4,5-tetrahidro-1h-(1,4)benzodiazepin-3-hidroksamat sebagai matriks penghambat metaloproteinase
ID20809A (id) Asam diaminokarboksilat tersubstitusi
NL1016815A1 (nl) Oximester-fotoinitiatoren.
TR199802289A3 (tr) Fosfonasit-ikame etmis benzazepinon-n-asetikasit türevleri.
NL1014361A1 (nl) Bevestigingsorgaan.
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
ID26379A (id) Katalis asam padat
ID28810A (id) Senyawa-senyawa amida-omega asam n-arilsulfonilamino
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
ATE369342T1 (de) 2,5-disubstituierte 3-mercaptopentansaure
DK1164845T3 (da) Landbrugskemisk sammensætning
ITTO20000385A0 (it) Composizione pesticida.
ITBO990671A0 (it) Maniglione antipanico.
IT1311662B1 (it) Struttura di calzatura.
TR200001070A3 (tr) Izosiyanat içeren baglayicilar.
ID30120A (id) DERIVAT-DERIVAT ASAM ARENEKARBOKSILIK α-(1-PIPERAZINIL)-ASETAMIDO SEBAGAI AGEN-AGEN ANTIDIABETIS
ES1044046Y (es) Valla.
NL1015547A1 (nl) Zeef.
ITTO990195V0 (it) Soletta sottopiede.
ES1044233Y (es) Calzado convertible.
ES1042496Y (es) "pilona sumible".
ES1044367Y (es) Piñata mejorada.
ID28064A (id) Proses produksi asam karboksilat aromatik
IT1311642B1 (it) Struttura di calzatura,
ES1044045Y (es) Valla mejorada.